Anabela Cardoso, MD

Anabela Cardoso, MD, is the senior vice president of immunology medical affairs at Eli Lilly and Company.

Articles by Anabela Cardoso, MD

Q&A Part 2: Reviewing the Significance of Lebrikizumab for Patients With Skin of Color, With Anabela Cardoso, MD

ByAnabela Cardoso, MD,Kaitlyn Bader, Assistant Managing Editor

July 2nd 2025

Anabela Cardoso, MD, reflects on specific data from the phase 3b ADmirable trial evaluating the safety and efficacy of lebrikizumab in patients with moderate to severe AD and pigmented skin.

Q&A Part 1: Reviewing the Significance of Lebrikizumab for Patients With Skin of Color, With Anabela Cardoso, MD

ByAnabela Cardoso, MD,Kaitlyn Bader, Assistant Managing Editor

June 20th 2025

Anabela Cardoso, MD, shares data from the phase 3b ADmirable trial—the first study to evaluate the safety and efficacy of lebrikizumab in patients with moderate to severe AD and pigmented skin.

Reviewing 3 Key Lebrikizumab Abstracts From AAD 2025

ByKaitlyn Bader, Assistant Managing Editor,Anabela Cardoso, MD

March 11th 2025

Anabela Cardoso, MD, discussed lebrikizumab’s efficacy in improving itch, skin pain, sleep disturbance, and long-term management in atopic dermatitis.

Late-Breaking Data: Baricitinib Shows Rapid Hair Regrowth in Adolescents With Severe Alopecia Areata

ByKaitlyn Bader, Assistant Managing Editor,Anabela Cardoso, MD

March 9th 2025

Anabela Cardoso, MD, provides data on the phase 3 BRAVE-AA-PEDS trial, the largest JAK inhibitor study dedicated to adolescents with severe alopecia areata, at AAD.